Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, June 1998, p. 1424-1427, Vol. 42, No. 6
Evans Memorial Department of Clinical
Research, Boston Medical Center, and Department of Medicine, Boston
University School of Medicine, Boston, Massachusetts
Received 29 January 1998/Returned for modification 5 March
1998/Accepted 6 April 1998
The antifungal activity of the nucleoside analog 3'-deoxyadenosine
(cordycepin) was studied in a murine model of invasive candidiasis.
When protected from deamination by either deoxycoformycin or
coformycin, both of which are adenosine deaminase inhibitors, cordycepin exhibited potent antifungal efficacy, as demonstrated by
prolongation of survival and a decrease in CFU in the kidneys of mice
treated with cordycepin plus an adenosine deaminase inhibitor. The
antifungal effect was seen with three different Candida
isolates: Candida albicans 64, a relatively
fluconazole-resistant clinical isolate of C. albicans (MIC,
16 µg/ml), and the fluconazole-resistant Candida krusei.
Cordycepin and related compounds may provide another avenue for the
discovery of clinically useful antifungal drugs.
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Antifungal Activity of 3'-Deoxyadenosine
(Cordycepin)
*
Corresponding author. Mailing address: Boston Medical
Center, E336, 88 E. Newton St., Boston, MA 02181. Phone: (617)
638-7905. Fax: (617) 638-8070. E-mail:
asugar{at}med-med1.bu.edu.
Publication no. 011 from the Collaborative Medical Mycology Program
(Pfizer Inc., Roerig Division; Phytera; Scriptgen Pharmaceuticals; and Section of Infectious Diseases, Boston Medical Center).
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |